ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Anne Favret, MD

VCS Physicians

Anne Favret, MD Headshot

Caring for women with breast cancer is a privilege. I am tasked with determining the very best treatment for each individual patient and working collaboratively with them on their journey.

Work and Credentials:

Primary Location

Fairfax Office


Medical Oncologist

Board Certification

Medical Oncology


Stanford University, Medical Oncology


Georgetown University


Georgetown University

Medical School

Temple University


Catholic University

Anne Favret, M.D. received her medical degree from Temple University and completed her internship and residency at Georgetown University Hospital. During her fellowship at Stanford University, she developed an interest in clinical research for breast cancer and has published several review articles, original research papers and a book chapter in the area of breast cancer management. Dr. Favret has also regularly spoken within the community and to news sources on the subject of breast cancer. In 2014, she was featured in Forbesmagazine for her expertise in breast cancer detection methods.

Dr. Favret is a member of the American Society of Clinical Oncology and stays active with tumor boards and local support groups. Having made patient care a top priority, she has received several awards throughout her career, including Top Doctor and Best Doctor honors in Washingtonian magazine, Virginia Living Magazine, and the Washington Post. Dr. Favret serves on the Executive Committee and is the Co-director of Breast Research for Virginia Cancer Specialists. She also serves on the Breast Committee for US Oncology.

Dr. Favret enjoys spending time with her family, including her three children. Her leisure time is spent cooking, running, entertaining, and going to the beach.










Practice Blog

January 24, 2019

Northern Virginia Magazine interviews Dr. Anne Favret in their "Spotlight on Top Oncologists" February 2019

Read More

Physician Publications

February 1, 2020

2020 Northern Virginia Magazine Top Doctors

Read More
July 29, 2016

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.

Read More
November 1, 2015

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Read More

More Publications by Anne Favret, MD

September 3, 2013

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Read More
February 2, 2013

Expert Insight: Genomic Variants Used To Further Stratify Risk in Breast Cancer

Read More
November 1, 2009

Dose intensity in early-stage breast cancer: a community practice experience.

Read More
April 1, 2007

HER2-positive advanced breast cancer

Read More
September 1, 1999

Multidisciplinary Management of Locally Advanced Breast Cancer

Read More

Clinical Trials (2)

Clinical Trial 20431

A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Clinical Trial 20284

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)

Primary Location

Fairfax Office Office

Fairfax Office

Learn More

Other Locations


November 1, 2020

Washingtonian Magazine Top Doctors 2020

December 1, 2019

2019 Washingtonian magazine Top Doctors

January 1, 2019

Northern Virginia Magazine Top Doctor 2019

January 1, 2018
Northern Virginia Magazine Top Doctors 2018

Northern Virginia Magazine Top Doctors 2018

January 1, 2019
Virginia Living Magazine Top Doctors 2018

Top Doctors Virginia Living Magazine 2018

September 9, 2016
Washingtonian Magazine

Washingtonian Top Doctor 2016

December 31, 2013
Washingtonian Magazine

Washingtonian Top Doctor 2015

December 31, 2013
Virginia Living Magazine

Top Doctor 2014

May 31, 2013
Super Doctors

Washington Post Super Doctors 2013

January 31, 2013
Northern Virginia Magazine

Top Doctor 2013